A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Biocad
- Target Recruit Count
- 206
- Registration Number
- NCT04397562
- Locations
- 🇷🇺
State Budgetary Healthcare Institution Kaluga region "Kaluga Regional Clinical Hospital", Kaluga, Russian Federation
🇷🇺State Budget Institution of the Republic of Dagestan "Republican Clinical Hospital", Machačkala, Russian Federation
🇷🇺A.N. Bakulev National Medical Research Center of Cardiovascular Surgery, Moscow, Russian Federation
Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Biocad
- Target Recruit Count
- 154
- Registration Number
- NCT04227366
- Locations
- 🇷🇺
Research Institute of Rheumotology, Moscow, Russian Federation
Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- Biocad
- Target Recruit Count
- 28
- Registration Number
- NCT04060264
- Locations
- 🇷🇺
Federal State Budgetary Educational Institution of Higher Education "Academician I.P. Pavlov First St. Petersburg State Medical University" of the Ministry of Healthcare of Russian Federation, Saint Petersburg, Russian Federation
Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Biocad
- Target Recruit Count
- 271
- Registration Number
- NCT04056897
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of Nizhny Novgorod region "Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod", Nizhny Novgorod, Russian Federation
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
- Conditions
- Healthy Subjects
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Biocad
- Target Recruit Count
- 78
- Registration Number
- NCT04027803
- Locations
- 🇷🇺
Limited Liability Company Research Center Eco-Bezopasnost (OOO Research Center Eco-Bezopasnost), Saint Petersburg, Russian Federation
Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma
- Conditions
- MelanomaMelanoma Metastatic
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Biocad
- Target Recruit Count
- 117
- Registration Number
- NCT03913923
- Locations
- 🇧🇾
State Institution "N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology", The Settlement Of Lesnoy, Minsk District, Belarus
🇧🇾Healthcare Institution "Minsk Municipal Clinical Oncolo-gy Dispensary" (MMCOD), Minsk, Belarus
🇷🇺Clinical Oncologic Dispensary No. 2, Sochi, Krasnodar Territory, Russian Federation
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)
- Conditions
- Cervical CancerCervical Cancer MetastaticCervical Cancer Recurrent
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- Biocad
- Target Recruit Count
- 49
- Registration Number
- NCT03912402
- Locations
- 🇷🇺
City Hospital No. 5, Barnaul, Altai Krai, Russian Federation
🇷🇺Arkhangelsk Clinical Oncology Dispensary, Arkhangel'sk, Arkhangelsk Oblast, Russian Federation
🇷🇺Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine, Chelyabinsk, Chelyabinsk Oblast, Russian Federation
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC
- Conditions
- Non-Squamous Non-Small Cell Neoplasm of Lung
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Biocad
- Target Recruit Count
- 292
- Registration Number
- NCT03912389
- Locations
- 🇨🇿
Regional Hospital Liberec, Liberec, Czechia
🇨🇿University Hospital Olomouc, Olomouc, Czechia
🇨🇿University Hospital Ostrava, Ostrava, Czechia
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)
- Conditions
- Cervical Cancer
- Interventions
- Biological: BCD-100Biological: BevacizumabOther: Placebo
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Biocad
- Target Recruit Count
- 316
- Registration Number
- NCT03912415
- Locations
- 🇨🇳
Shanghai Tenth People's Hospital, Shanghai, China
🇬🇪High technology Hospital Medcenter, Batumi, Georgia
🇬🇪Acad. F.Todua Medical center "Research institute of Clinical Medicine", Tbilisi, Georgia
First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects
- Conditions
- Healthy
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Biocad
- Target Recruit Count
- 15
- Registration Number
- NCT03912441
- Locations
- 🇷🇺
Medical Center "Eco-Safety", Saint Petersburg, Russian Federation